April 24th, 2011 - Volume 25 - Issue 7
pp: 885-1015

Concise Communications

The natural history of liver cirrhosis in HIV–hepatitis C virus-coinfected patients

López-Diéguez, María; Montes, María L; Pascual-Pareja, José F; More

AIDS. 25(7):899-904, April 24th, 2011.

Week 48 analysis of once-daily vs. twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients

Cahn, Pedro; Fourie, Jan; Grinsztejn, Beatriz; More

AIDS. 25(7):929-939, April 24th, 2011.

Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection

Gay, Cynthia L; Mayo, Ashley J; Mfalila, Chelu K; More

AIDS. 25(7):941-949, April 24th, 2011.

Concise Communication

Hospitalization for severe malnutrition among HIV-infected children starting antiretroviral therapy

Prendergast, Andrew; Bwakura-Dangarembizi, Mutsa F; Cook, Adrian D; More

AIDS. 25(7):951-956, April 24th, 2011.

Safety and effectiveness of BufferGel and 0.5% PRO2000 gel for the prevention of HIV infection in women

Abdool Karim, Salim S; Richardson, Barbra A; Ramjee, Gita; More

AIDS. 25(7):957-966, April 24th, 2011.

The use of atazanavir in HIV-infected patients with liver cirrhosis: lack of hepatotoxicity and no significant changes in bilirubin values or model for end-stage liver disease score

Rodriguez, Jose M; Hermida, Jose M; Casado, Jose L; More

AIDS. 25(7):1006-1009, April 24th, 2011.

Reply to comment on ‘pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients’

Barrail-Tran, Aurélie; Yazdanpanah, Yazdan; Goldwirt, Lauriane; More

AIDS. 25(7):1011-1012, April 24th, 2011.